Effect of Acitretin Versus Narrowband Ultraviolet B on Neopterin Level in Psoriatic Patients .
Evaluation of the Effect of Acitretin Versus Narrowband Ultraviolet B on Serum Neopterin Level in Psoriatic Patients .
1 other identifier
interventional
30
1 country
1
Brief Summary
To evaluate effect of acitretin versus Narrowband UVB on serum level of neopterin in psoriatic patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Jun 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 5, 2021
CompletedFirst Submitted
Initial submission to the registry
May 27, 2022
CompletedFirst Posted
Study publicly available on registry
June 2, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 5, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 5, 2023
CompletedJune 2, 2022
May 1, 2022
1 year
May 27, 2022
May 27, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Serum Neopterin in psoriasis
Measurement of Neopterin in psoriatic patients before and after treatment with NB-UVB, Acitretin and combination of both modalities using ELISA (enzyme-linked immunosorbent assay).
3 Months
Secondary Outcomes (1)
Treatment of psoriasis
3 Months
Study Arms (3)
Acitretin
ACTIVE COMPARATORPatients will Receive Acitretin (0.25-1 mg /kg/day )for 3months .
Narrowband ultraviolet B
ACTIVE COMPARATORPatients will receive Narrowband UVB( 3session /week ) for 3months.
Combination of Narrowband ultraviolet B and Acitretin
ACTIVE COMPARATORPatients will receive Acitretin (0.25-1 mg /kg/day ) and Narrowband UVB( 3session /week ) for 3 months.
Interventions
Acitretin is an oral retinoid (a derivative of vitamin A) given in a dose 0.25-1 mg /kg/day for 3months in psoriatic patients
Narrowband UVB is the most common form of phototherapy used to treat psoriasis, given 2-3 sessions per week for 3 successive months
Eligibility Criteria
You may qualify if:
- Patients with psoriasis diagnosed clinically Aged (15-60).
You may not qualify if:
- Patient with history of skin cancer.
- Patient with history of photosensitivity.
- Pregnancy and lactation.
- Liver failure.
- Renal failure.
- Patient with psoriatic artheritis.
- Patient with allergy to product or any of its components.
- Patient with poorly controlled dyslipidemia.
- Patient receiving tetracyclines.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
South Valley University
Qina, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Resident doctor
Study Record Dates
First Submitted
May 27, 2022
First Posted
June 2, 2022
Study Start
June 5, 2021
Primary Completion
June 5, 2022
Study Completion
June 5, 2023
Last Updated
June 2, 2022
Record last verified: 2022-05